Scarica l'app Stockscreener
1.80
0.00%
0.00
Precedente Chiudi:
$1.80
Aprire:
$1.81
Volume 24 ore:
346.10K
Relative Volume:
0.19
Capitalizzazione di mercato:
$120.58M
Reddito:
-
Utile/perdita netta:
$-122.44M
Rapporto P/E:
-0.7986
EPS:
-2.254
Flusso di cassa netto:
$-103.79M
1 W Prestazione:
+0.56%
1M Prestazione:
-6.25%
6M Prestazione:
-81.15%
1 anno Prestazione:
-49.58%
Intervallo 1D:
$1.785
$1.8383
Intervallo di 1 settimana:
$1.73
$1.8383
Portata 52W:
$1.40
$12.25
Engene Therapeutics Inc Stock (ENGN) Company Profile
Nome
Engene Therapeutics Inc
Settore
Industria
Telefono
(514) 332-4888
Indirizzo
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Therapeutics Inc
|
1.80 | 117.90M | 0 | -122.44M | -103.79M | -2.254 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Engene Therapeutics Inc Stock (ENGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | WBB Securities | Buy |
| 2026-01-30 | Iniziato | Jefferies | Buy |
| 2025-11-11 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-02-18 | Iniziato | Piper Sandler | Overweight |
| 2025-02-14 | Downgrade | UBS | Buy → Neutral |
| 2024-12-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-27 | Iniziato | Raymond James | Outperform |
| 2024-11-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-08-28 | Iniziato | Oppenheimer | Outperform |
| 2024-04-22 | Iniziato | Wells Fargo | Overweight |
| 2024-04-15 | Iniziato | Guggenheim | Buy |
| 2024-03-28 | Iniziato | UBS | Buy |
| 2024-03-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-20 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Engene Therapeutics Inc Borsa (ENGN) Ultime notizie
enGene Therapeutics Inc. Revenue Breakdown – BOATS:ENGNW - TradingView
enGene Therapeutics Inc. Revenue Breakdown – NASDAQ:ENGN - TradingView
Executive options at enGene Therapeutics (ENGN) vesting over 4 years - Stock Titan
enGene Therapeutics (NASDAQ: ENGN) outlines insider RSUs and options - Stock Titan
enGene Therapeutics (ENGN) sees 5.0% beneficial stake reported by Acorn group - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
enGene Holdings appoints new chairman to guide growth - The Globe and Mail
enGene Highlights Progress of Lead Bladder Cancer Therapy - TipRanks
enGene Therapeutics (NASDAQ: ENGN) posts 54% response in NMIBC study - Stock Titan
EnGene Therapeutics (ENGN) price target decreased by 64.55% to 8.72 - MSN
enGene Therapeutics announces board changes - The Pharma Letter
enGene names Michael Heffernan board chairman as Richard Glickman steps down - Bitget
enGene appoints Michael Heffernan as board chairman By Investing.com - Investing.com Australia
enGene appoints Michael Heffernan as board chairman - Investing.com
Dr. Richard Glickman resigns as chairman of enGene Therapeutics - TradingView
enGene Therapeutics (Nasdaq: ENGN) names new chair, plans BLA filing - Stock Titan
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones - Business Wire
Bronstein, Gewirtz & Grossman, LLC Encourages enGene Therapeutics - The National Law Review
enGene Therapeutics (ENGN) JMP Hematology and Oncology Summit 2024 Summary - Quartr
enGene reports 54% response rate in bladder cancer trial - Investing.com
Piper Sandler downgrades enGene Therapeutics (ENGN) - MSN
enGene Therapeutics Inc. Actuals & Estimates (NASDAQ:ENGN) - TradingView
enGene Therapeutics Inc. Financial Disclosures & Filings - TradingView
Enterprise value to EBITDA forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Enterprise value to revenue forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
ENGNenGene Therapeutics Inc Volatility & Greeks - Finviz
Price to earnings forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Enterprise value to EBIT forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Price to sales forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
enGene Therapeutics Inc. Actuals & Estimates (FWB:S0N0) - TradingView
Layoff Tracker: Biogen axes ‘small number’ of Apellis roles after $5.6B buy - BioSpace
ENGN Forecast — Price Target — Prediction for 2027 - TradingView
Number of shareholders of enGene Therapeutics Inc. – NASDAQ:ENGNW - TradingView
A Quick Look at Today's Ratings for EnGene Therapeutics(ENGN.US), With a Forecast Between $2 to $6 - Moomoo
enGene Therapeutics - The Business Journals
Morgan Stanley Downgrades EnGene to Underweight From Equalweight - Moomoo
ENGN Downgraded by Morgan Stanley -- Rating Changed to Underweig - GuruFocus
EnGene Shares Fall After Morgan Stanley Downgrade - Moomoo
enGene Therapeutics (ENGN) lifts restructuring and retention cost estimates - Stock Titan
enGene Therapeutics Positions Detalimogene for NMIBC Opportunity Amid Expanding Oncology Landscape - Streetwise Reports
EnGene Detalimogene's Durability Profile 'Not Competitive,' Morgan Stanley Says - marketscreener.com
Morgan Stanley Downgrades enGene to Underweight From Equalweight - marketscreener.com
Morgan Stanley Downgrades EnGene Therapeutics(ENGN.US) to Sell Rating - Moomoo
Morgan Stanley cuts Engene stock rating on reduced sales outlook - Investing.com
Morgan Stanley cuts Engene stock rating on reduced sales outlook By Investing.com - Investing.com UK
enGene Therapeutics (ENGN) director awarded options for 31,000 shares - Stock Titan
enGene Therapeutics (ENGN) grants director 31,000 stock options - Stock Titan
enGene Therapeutics (ENGN) director receives 31,000 stock options at $1.75 strike - Stock Titan
[Form 4] enGene Therapeutics Inc. Insider Trading Activity - Stock Titan
enGene Therapeutics (ENGN) director awarded 31,000 stock options - Stock Titan
Director Michael Heffernan of enGene (ENGN) awarded options on 31,000 shares - Stock Titan
Engene Therapeutics Inc Azioni (ENGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.84%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):